Why the study?
Peripheral arterial disease is the third leading cause of atherosclerotic morbidity yet remains widely underdiagnosed and undertreated.
Answers are grounded in this paper and cite their sources.
This narrative review highlights the importance of PAD screening, risk factor modification, and individualized antithrombotic therapy to reduce major adverse cardiovascular and limb outcomes.
Peripheral arterial disease (PAD) is the third leading cause of atherosclerotic morbidity after coronary heart disease and stroke yet is widely underdiagnosed and undertreated. Treatment of risk factors such as diabetes and cigarette smoking can benefit patients with PAD. Patients should have adequate blood pressure and lipid control to decrease clinical manifestations and symptoms of PAD. Use of antithrombotic medications should be individualized to the patient depending on the presence of symptoms, revascularization, and comorbidities. All patient care providers, including physicians, pharmacists, nurse practitioners, and physician assistants, should incorporate PAD screening in their at-risk patients to improve access for appropriate earlier diagnosis, initiation of guideline directed therapy, and risk factor modification to reduce both major adverse CV and limb outcomes. The purpose of this narrative review is to provide an overview of PAD and summarize clinical trial evidence and guideline recommendations for screening and treatment to increase awareness among health care providers to ultimately have a positive impact on patient care.
No takes yet. Share an insight, caveat, or question.
Chilbert et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: